Cinacalcet Tablet, Film Coated
Product Images NDC 70518-4615

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Cinacalcet (NDC 70518-4615). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cinacalcet-structure (40332509 Df24 41a0 A75c 86d556cf0c50 01)

Chemical structure of Cinacalcet hydrochloride, showing the molecular arrangement including trifluoromethyl, aromatic rings, and amine groups as part of the compound.*

FDA Label Image

Figure 1 (40332509 Df24 41a0 A75c 86d556cf0c50 02)

A line graph comparing iPTH (pg/mL) levels over 26 weeks between Cinacalcet and placebo groups. The x-axis represents weeks (0 to 26) and the y-axis shows iPTH levels from 0 to 1000 pg/mL. The Cinacalcet group shows a decreasing trend in iPTH levels, while the placebo group displays relatively stable levels with slight fluctuations.*

FDA Label Image

Figure 2 (40332509 Df24 41a0 A75c 86d556cf0c50 03)

A line graph comparing Ca x P (mg/dL) levels over 26 weeks between Cinacalcet and placebo groups. The x-axis shows time in weeks, and the y-axis shows Ca x P levels. Cinacalcet is represented by a solid red line with markers, showing a decrease over time, while placebo is represented by a black dashed line, remaining relatively stable.*

FDA Label Image

Figure-3 (40332509 Df24 41a0 A75c 86d556cf0c50 04)

A line graph depicting calcium levels (mg/dL) over time in weeks for patients with parathyroid carcinoma. The x-axis shows weeks from baseline (B) through 80 weeks, divided into titration and maintenance phases. The y-axis shows calcium levels ranging from 8 to 16 mg/dL, with data points and error bars for various weeks, indicating trends in serum calcium over the study period.*

FDA Label Image

Figure-4 (40332509 Df24 41a0 A75c 86d556cf0c50 05)

A line graph illustrating average calcium levels (mg/dL) over 80 weeks in patients with intractable pHPT, showing a decrease during titration from baseline followed by stable levels during maintenance. The x-axis represents time in weeks, and the y-axis shows calcium concentration with error bars indicating variability at each time point.*

FDA Label Image

Mm1 (Cinacalcet 30mg 70518 4615 00)

Cinacalcet 30 mg film-coated tablets packaging label showing quantity of 50 tablets per box. The label includes the NDC (70518-4615-00), manufacturer Strides Pharma Inc., and repackager RemedyRepack Inc. It provides storage instructions and advises to see the insert for usual dosage.*

FDA Label Image

Remedy_label (Remedy Label)

Cinacalcet 30 mg tablet label showing a single film-coated tablet with NDC 70518-4615-01. The label indicates it is repackaged by RemedyRepack Inc., Indiana, PA. The original manufacturer is Strides Pharma Inc., Lambertville, NJ. Storage instructions and dosage information to see insert are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.